Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: Structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex

Journal of Medicinal Chemistry

Volumn 48, Issue 18, 2005, Pages 5659-5665

  Petrova, Tatiana ^a,f   Steuber, Holger ^b   Hazemann, Isabelle ^a   Cousido Siah, Alexandra ^a   Mitschler, Andre ^a   Chung, Roland ^c   Oka, Mitsuru ^d   Klebe, Gerhard ^b   El Kabbani, Ossama ^c   Joachimiak, Andrzej ^e   Podjarny, Alberto ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c MONASH UNIVERSITY   (Australia)

^d SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

^e ARGONNE NATIONAL LABORATORY   (United States)

^f INSTITUTE OF MATHEMATICAL PROBLEMS OF BIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; AMIDE; FIDARESTAT; LEUCINE; MUTANT PROTEIN; PROLINE; SORBINIL; TRYPTOPHAN;

ARTICLE; COMPLEX FORMATION; DRUG BINDING; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; ENERGY; ENTHALPY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME STRUCTURE; HUMAN; HYDROGEN BOND; NONHUMAN; NUCLEOTIDE SEQUENCE; STRUCTURE ANALYSIS; SWINE; X RAY CRYSTALLOGRAPHY;

ALDEHYDE REDUCTASE; BINDING SITES; CALORIMETRY; CRYSTALLIZATION; HOLOENZYMES; HUMANS; IMIDAZOLIDINES; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; THERMODYNAMICS;

EID: 24744457100     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050424+     Document Type: Article

References (38)

1. Jez, J. M.; Bennett, M. J.; Schlegel, B. P.; Lewis, M.; Penning, T. M. Comparative anatomy of the aldo-keto reductase superfamily. Biochem. J. 1997, 326, 625-636.
2. Warren, J. C.; Murdock, G. L.; Ma, Y.; Goodman, S. R.; Zimmer, W. E. Molecular cloning of testicular 20α-hydroxysteroid dehydrogenase: identity with aldose reductase. Biochemistry 1993, 32, 1401-1406.
3. Dunlop, M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int.-Suppl. 2000, 77, S3-S12.
4. Kinoshita, J. H.; Nishimura, C. The involvement of aldose reductase in diabetic complications. Diabetes Metab. Rev. 1988, 4, 323-337.
5. Yabe-Nishimura, C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev. 1998, 50, 21-33.
6. Costantino, L.; Rastelli, G.; Gamberini, M. C.; Barlocco, D. Pharmacological approaches to the treatment of diabetic complications. Expert Opin. Ther. Pat. 2000, 10, 1245-1262.
7. Oates, P. J.; Mylari, B. L. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin. Invest. Drugs 1999, 8, 1-25.
8. Pfeifer, M. A.; Schumer, M. P.; Gelber, D. A. Aldose reductase inhibitors: the end of an era or the need for different trial design. Diabetes 1997, 46, S82-S89.
9. Miyamoto, S. Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications. Expert Opin. Ther. Pat. 2002, 12, 621-631.
10. Sato, S.; Kador, P. F. Inhibition of aldehyde reductase by aldose reductase inhibitors. Biochem. Pharmacol. 1990, 40, 1033-1042.
11. Ratliff, D. M.; Van der Jagt, D. J.; Eaton, R. P.; Van der Jagt, D. L. Increased levels of methylglyoxal-metabolizing enzymes in mononuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxase I, and glyoxalase II. A clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81, 488-492.
12. Urzhumtsev, A.; Tête-Favier, F.; Mitschler, A.; Barbanton, J.; Barth, P.; Urzhumtseva, L.; Biellmann, J.-F.; Podjarny, A. D.; Moras, D. A. "Specificity" pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 1997, 5, 601-612.
13. El-Kabbani, O.; Judge, K.; Ginell, S. L.; Myles, D. A.; DeLucas, L. J.; Flynn, T. G. Structure of porcine aldehyde reductase holoenzyme. Nat. Struct. Biol 1995, 2, 687-692.
14. Da Settimo, F.; Primofiore, G.; Da Settimo, A.; La Motta, C.; Taliani, S.; Simorini, F.; Novellino, E.; Greco, G.; Lavecchia, A.; Boldrini, E. [1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: A new class of selective aldose reductase inhibitors. J. Med. Chem. 2001, 44, 4359-4369.
15. Oka, M.; Matsumoto, Y.; Sugiyama, S.; Tsuruta, N.; Matsushima, M. A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′- dioxyspiro[chroman-4,4′-imidazoline]-2-carboxamide (fidarestat): Its absolute configuration and interaction with aldose reductase by X-ray crystallography. J. Med. Chem. 2000, 43, 2479-2483.
16. Kurono, M.; Fujiwara, I.; Yoshida, K. Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase. Biochemistry 2001, 40, 8216-8226.
17. Sarges, R.; Oates, P. J. Aldose reductase inhibitors: Recent developments. Prog. Drug Res. 1993, 40, 99-161.
18. Eggler, J. F.; Larson, E. R.; Lipinski, C. A.; Mylari, B. L.; Urban, F. J. A perspective of aldose reductase inhibitors. In Advances in Medicinal Chemistry; Jai Press: Greenwich, CT, 1993; Vol. 2, pp 197-246.
19. Larson, E. R.; Lipinski, C. A.; Sarges, R. Medicinal chemistry of aldose reductase inhibitors. Med. Chem. Rev. 1988, 8, 159-186.
20. El-Kabbani, O.; Carper, D. A.; McGowan, M. H.; Devedjiev, Y.; Rees-Milton, K. J.; Flynn, T. G. Studies on the inhibitor-binding site of porcine aldehyde reductase: crystal structure of the holoenzyme-inhibitor ternary complex. Proteins: Struct., Funct., Genet. 1997, 29, 186-192.
21. El-Kabbani, O.; Old, S. E.; Ginell, S. L.; Carper, D. A. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites. Mol. Vision 1999, 5, 20-26.
22. Barski, O. A.; Gabbay, K. H.; Bohren, K. M. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry 1996, 35, 14276-14280.
23. El-Kabbani, O.; Rogniaux, H.; Earth, P.; Chung, R.; Fletcher, E.; Dorsselaer, A.; Podjarny, A. Aldose and aldehyde reductases: correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site. Proteins: Struct. Funct. Genet. 2000, 41, 407-414.
24. El-Kabbani, O.; Darmanin, C.; Schneider, T. R.; Hazemann, I.; Ruiz, F.; Oka, M.; Joachimiak, A.; Schulze-Briese, C.; Tomizaki, T.; Mitschler, A.; Podjarny, A. Ultra high-resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: Implications for the binding of cyclic imide inhibitors. Proteins 2004, 55, 805-813.
25. El-Kabbani, O.; Darmanin, C.; Oka, M.; Schulze-Briese, C.; Tomizaki, T.; Hazemann, I.; Mitschler, A.; Podjarny, A. High resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor fidarestat: Stereospecific interaction between the enzyme and a cyclic imide inhibitor. J. Med. Chem. 2004, 47, 4530-4537.
26. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
27. Howard, E. I.; Sanishvili, R.; Cachau, R. E.; Mitschler, A.; Chevrier, B.; Barth, P.; Lamour, V.; Van Zandt, M.; Sibley, E.; Bon, C.; Moras, D.; Schneider, T. R.; Joachimiak, A.; Podjarny, A. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 Å. Proteins 2004, 55, 792-804.
28. El-Kabbani, O.; Carbone, V.; Darmanin, C.; Oka, M.; Mitschler, A.; Podjarny, A.; Schulze-Briese, C.; Chung, R. P.-T. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: Implications for Inhibitor binding and selectivity. J. Med. Chem., in press.
29. Chung, S.; La Mendola, J. Cloning and sequence determination of human placental aldose reductase gene. J. Biol. Chem. 1989, 264, 4775-4777.
30. McPherson, A. Crystallization of macromolecules: general principles. Methods Enzymol. 1985, 114, 112-120.
31. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
32. Navaza, J. Amore, an automated package for molecular refinement. Acta Crystallogr., Sect. A 1994, 50, 157-163.
33. Sheldrick, G.; Schneider, T. SHELXL: high-resolution refinement. Methods Enzymol. 1997, 277, 319-343.
34. McRee, D. E. XtalView/Xfit. A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 1999, 125, 156-165.
35. Holdgate, G. A. Making cool drugs hot: Isothermal titration calorimetry as a tool to study binding energetics. BioTechniques 2001, 31, 164-184.
36. Barski, O. A.; Gabbay, K. H.; Grimshaw, C. E.; Bohren, K. M. Mechanism of human aldose reductase: characterization of the active site pocket. Biochemistry 1995, 34, 11264-11275
37. Mizuno, K.; Yamaguchi, T.; Unoue, A.; Tomiya, N.; Unno, R.; Miura, K.; Usui, T.; Matsumoto, Y.; Kondo, Y.; Yoshina, S.; Kondo, Y.; Sato, M.; Matsubara, A.; Kato, N.; Nakano, K.; Shirai, M.; Inoue, T.; Awaya, J.; Asaeda, N.; Hayasaka, I.; Koide, M.; Hibi, C.; Ban, M.; Sawai, K.; Kurono, M. Profile of a new aldose reductase inhibitor (2S,4S)-6-Fluoro-2′,5′- dioxyspiro[chroman-4,4′-imidazoline]-2-carboxamide. Excerpta Med. 1990, 913, 89-96.
38. Poulsom, R. Inhibition of aldose reductase from human retina. Curr. Eye Res. 1987, 6, 427-32.